Le mode conseil est activé Arrêter
Pour la navigation rapide entre les blocs

Organisation: Alaunos Therapeutics

Nom de l'organisation
Alaunos Therapeutics Inc (formerly ZIOPHARM Oncology, Inc.)
Nom du pays
États-Unis
Pays d'enregistrement
États-Unis
Secteur économique
Production de médicaments et biotechnologies
Dette obligataire
-

explorer la base de données la plus complète

800 000

obligations globalement

Plus de 400

sources de prix

80 000

actions

9 000

ETF

suivre votre portefeuille de la manière la plus efficace
screener d'obligations
liste de surveillance
Excel ADD-IN
Obtenir l'accès

Dernières données pour

Cotations

Requête envoyé
Accès refusé
Envoyer la requête
Les cotations fournis par les fournisseurs d’information sont de nature indicative

Profile

Alaunos is a clinical-stage oncology-focused cell therapy company, focused on developing T-cell receptor (TCR) therapies based on its proprietary, non-viral Sleeping Beauty gene transfer platform and its unique cancer mutation hotspot TCR library, targeting common tumor-related mutations in key oncogenic genes including KRAS, TP53 and EGFR.

Récompenses

Actualités

16/02/2024 Alaunos Therapeutics: Other Events, Financial Statements And Exhibits
31/01/2024 Alaunos Therapeutics: Amendments To Articles Of Incorporation Or Bylaws; Change In Fiscal Year, Financial Statements And Exhibits
29/01/2024 Alaunos Therapeutics: Other Events, Financial Statements And Exhibits
20/01/2024 Alaunos Therapeutics: Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers
29/12/2023 Alaunos Therapeutics: Departure Of Directors Or Certain Officers; Election Of Directors; Appointment Of Certain Officers; Compensatory Arrangements Of Certain Officers, Regulation Fd Disclosure
Toutes les actualités de l'organisation

Documents

Etats financiers IFRS / US GAAP

2024
I q ang
2023
I q ang
II q ang
III q ang
IV q ang
2022
I q ang
II q ang
III q ang
IV q ang
2021
I q ang
II q ang
III q ang
IV q ang
2020
I q ang
II q ang
III q ang
IV q ang
2019
I q ang
II q ang
III q ang
IV q ang
2018
I q ang
II q ang
III q ang
IV q ang
2017
I q ang
II q ang
III q ang
IV q ang
2016
I q ang
II q ang
III q ang
IV q ang
2015
I q ang
II q ang
III q ang
IV q ang
2014
IV q ang
Afficher tout Masquer
Il faut s'enregistrer
Envoyer la demande d'accès accès

Actions

Dette obligataire par devise

Montrer tout Cacher

Codes

  • SIC
    2834 PHARMACEUTICAL PREPARATIONS
  • CIK
    0001107421
  • EIN
    84-1475642

Notations de crédit et notations d’ESG

Macroéconomie

Vous devez vous inscrire pour y accéder.